PT-141 (10mg)

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molecular weight of approximately 1,025 Da. It is a synthetic analogue of alpha-MSH developed from the linear peptide Melanotan II through lactam bridge cyclization between Asp and Lys residues.

Research has focused on PT-141's central nervous system activity through melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptor activation. Unlike peripherally-acting compounds, PT-141's mechanism operates through hypothalamic melanocortin circuitry. Preclinical studies in rodent and primate models have examined its effects on central nervous system signaling pathways, autonomic arousal responses, and hypothalamic-pituitary axis modulation. Clinical-stage research has documented its MC4R-mediated central effects, leading to FDA evaluation of bremelanotide through the regulatory pathway. Investigators have also explored broader melanocortin system research applications.

The mechanism of action involves selective activation of MC3R and MC4R in the medial preoptic area and paraventricular nucleus of the hypothalamus. Receptor binding triggers Gs-coupled cAMP signaling and downstream neuronal activation in autonomic centers, distinct from vascular or peripheral mechanisms.

Viking Labs synthesizes research-grade PT-141 at a USA-based cGMP facility. HPLC analysis confirms 99%+ purity on every batch. Certificate of Analysis, batch serialization, and sterile fill included.

Storage: Store lyophilized at -20C. Reconstituted at 2-8C, use within 21 days. The cyclic structure provides good solution stability.

For laboratory research use only. Not for human consumption.